Anakinra and peg stnf-r1 (DrugBank: Anakinra, sTNF-R1)
19 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
15 | Inclusion body myositis | 0 |
19 | Lysosomal storage disease | 0 |
28 | Systemic amyloidosis | 0 |
37 | Generalised pustular psoriasis | 0 |
41 | Giant cell arteritis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
49 | Systemic lupus erythematosus | 0 |
50 | Dermatomyositis | 0 |
56 | Behcet disease | 0 |
65 | Primary immunodeficiency | 0 |
84 | Sarcoidosis | 0 |
86 | Pulmonary arterial hypertension | 0 |
97 | Ulcerative colitis | 0 |
106 | Cryopyrin-associated periodic syndrome | 0 |
107 | Juvenile idiopathic arthritis [Systemic juvenile idiopathic arthritis (~Mar 2018)] | 0 |
266 | Familial mediterranean fever | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00537667 (ClinicalTrials.gov) | August 2001 | 27/9/2007 | The SPECTRA Study | A Single Centre, Open-Label, Randomised, Study to Evaluate the Effect of Anakinra (r-metHuIL-1ra) Alone and in Combination With PEGylated Recombinant Methionyl Human Soluble Tumour Necrosis Factor Receptor Type I (PEG sTNF-RI) on Synovial Inflammation in Subjects With Rheumatoid Arthritis. | Rheumatoid Arthritis | Drug: anakinra;Drug: anakinra and PEG sTNF-R1 | Amgen | NULL | Terminated | 18 Years | N/A | Both | 22 | Phase 2 | NULL |